BRIEF published on 03/14/2025 at 15:21, 1 year 4 months ago JP Morgan Chase Reduces Stake in ABIVAX Actions Abivax Regulation Threshold Crossing JP Morgan Chase
BRIEF published on 03/13/2025 at 12:43, 1 year 4 months ago JP Morgan Crosses Threshold in ABIVAX Voting Rights Actions Abivax Threshold Crossing JP Morgan
BRIEF published on 02/25/2025 at 18:05, 1 year 5 months ago ABIVAX: Information on capital and voting rights as of January 31, 2025 Euronext Paris Share Capital Voting Rights Abivax Finances
BRIEF published on 02/21/2025 at 08:35, 1 year 5 months ago Abivax to Hold Expert Webcast on Ulcerative Colitis Abivax Obefazimod Ulcerative Colitis Clinical Trial Webcast Event
PRESS RELEASE published on 02/21/2025 at 08:30, 1 year 5 months ago Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025 Abivax to host Key Opinion Leader (KOL) webcast featuring Dr. David Rubin on March 17, 2025, discussing ulcerative colitis treatment landscape and ABTECT Phase 3 Trial Abivax Ulcerative Colitis Webcast ABTECT Phase 3 Trial Key Opinion Leader
BRIEF published on 02/18/2025 at 10:08, 1 year 5 months ago Crossing of threshold at ABIVAX: statement from Sofinnova Voting Rights Abivax Threshold Crossing Product Development Sofinnova Partners
BRIEF published on 01/28/2025 at 08:35, 1 year 6 months ago Abivax unveils its financial calendar for 2025 Financial Results Biotechnology Half-yearly Report Financial Calendar Abivax
PRESS RELEASE published on 01/28/2025 at 08:30, 1 year 6 months ago Abivax Publishes 2025 Financial Calendar Abivax publishes its 2025 financial calendar, detailing key financial communications throughout the year. The company is focused on developing therapies for chronic inflammatory diseases Biotechnology Abivax Therapeutics Chronic Inflammatory Diseases 2025 Financial Calendar
BRIEF published on 01/27/2025 at 18:05, 1 year 6 months ago ABIVAX: Update on shares and voting rights as of December 31, 2024 Share Capital Voting Rights Actions Abivax Financial Transparency
BRIEF published on 01/23/2025 at 22:10, 1 year 6 months ago Abivax presents seven abstracts on Obefazimod at ECCO 2025 Biotechnology Abivax Obefazimod Ulcerative Colitis ECCO Congress 2025
Published on 08/11/2026 at 00:40, 5 hours 52 minutes ago CORRECTION FROM SOURCE: Fermi Announces Binding Lease Agreement with TensorWave
Published on 08/11/2026 at 00:25, 6 hours 7 minutes ago Empress Reports 2026 Second Quarter Financial Results
Published on 08/10/2026 at 23:35, 6 hours 57 minutes ago NioCorp Project to Expand Production to 8 Made-in-USA Critical Minerals Over a 40-Year Mine Life with an Estimated $4.1 Billion Pre-Tax NPV8%
Published on 08/10/2026 at 23:30, 7 hours 2 minutes ago Condor and Element79 Agree on Restructured Terms for Lucero Project
Published on 08/10/2026 at 23:25, 7 hours 7 minutes ago Ur-Energy Reports Second Quarter 2026 Results
Published on 08/10/2026 at 22:15, 8 hours 17 minutes ago Amrize Files Form 10-Q for Second Quarter 2026
Published on 08/10/2026 at 22:05, 8 hours 27 minutes ago Immunic Appoints Elena Ridloff to Board of Directors
Published on 08/10/2026 at 20:24, 10 hours 8 minutes ago EQS-Adhoc: PNE AG updates on ongoing sales process
Published on 08/10/2026 at 19:35, 10 hours 57 minutes ago Kontron AG: All conditions of the mandatory tender offer of Ennoconn Corporation are met – Settlement will take place shortly
Published on 08/10/2026 at 18:29, 12 hours 2 minutes ago Fuller, Smith & Turner PLC: Director/PDMR Shareholdings
Published on 08/10/2026 at 18:00, 12 hours 32 minutes ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 11:53, 18 hours 38 minutes ago GUILLEMOT CORPORATION | Information regarding the total number of voting rights and shares 31/07/2026
Published on 08/10/2026 at 11:36, 18 hours 56 minutes ago GUILLEMOT CORPORATION| Weekly report share buyback from August 3 to August 7 2026
Published on 08/10/2026 at 09:22, 21 hours 10 minutes ago Number of shares and voting rights - July 2026 (In French only)
